Imperial College London
Alternate

ProfessorPaoloVineis

Faculty of Medicine, School of Public Health

Chair in Environmental Epidemiology
 
 
 
//

Contact

 

+44 (0)20 7594 3372p.vineis Website

 
 
//

Location

 

511Medical SchoolSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Wu:2023:10.1002/ijc.34340,
author = {Wu, WY-Y and Haider, Z and Feng, X and Heath, AK and Tjønneland, A and Agudo, A and Masala, G and Robbins, HA and Huerta, M-J and Guevara, M and Schulze, MB and Rodriguez-Barranco, M and Vineis, P and Tumino, R and Kaaks, R and Fortner, RT and Sieri, S and Panico, S and Nøst, TH and Sandanger, TM and Braaten, T and Johansson, M and Melin, B and Johansson, M},
doi = {10.1002/ijc.34340},
journal = {International Journal of Cancer},
pages = {2002--2010},
title = {Assessment of the EarlyCDT-Lung test as an early biomarker of lung cancer in ever-smokers - A retrospective nested case-control study in two prospective cohorts},
url = {http://dx.doi.org/10.1002/ijc.34340},
volume = {152},
year = {2023}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The EarlyCDT-Lung test is a blood-based autoantibody assay intended to identify high-risk individuals for low-dose computed tomography lung cancer screening. However, there is a paucity of evidence on the performance of the EarlyCDT-Lung test in ever-smokers. We conducted a nested case-control study within two prospective cohorts to evaluate the risk-discriminatory performance of the EarlyCDT-Lung test using pre-diagnostic blood samples from 154 future lung cancer cases and 154 matched controls. Cases were selected from those who had ever smoked and had a pre-diagnostic blood samples less than 3 years prior to diagnosis. Conditional logistic regression was used to estimate the association between EarlyCDT-Lung test results and lung cancer risk. Sensitivity and specificity of the EarlyCDT-Lung test were calculated in all subjects and subgroups based on age, smoking history, lung cancer stage, sample collection time before diagnosis and year of sample collection. The overall lung cancer odds ratios were 0.89 (95% CI, 0.34-2.30) for a moderate risk EarlyCDT-Lung test result and 1.09 (95% CI, 0.48-2.47) for a high-risk test result compared to no significant test result. The overall sensitivity was 8.4% (95% CI, 4.6-14) and overall specificity was 92% (95% CI, 87-96) when considering a high-risk result as positive. Stratified analysis indicated higher sensitivity (17%, 95% CI, 7.2-32.1) in subjects with blood drawn up to 1 year prior to diagnosis. In conclusion, our study does not support a role of the EarlyCDT-Lung test in identifying the high-risk subjects in ever-smokers for lung cancer screening in the EPIC and NSHDS cohorts.
AU  - Wu,WY-Y
AU  - Haider,Z
AU  - Feng,X
AU  - Heath,AK
AU  - Tjønneland,A
AU  - Agudo,A
AU  - Masala,G
AU  - Robbins,HA
AU  - Huerta,M-J
AU  - Guevara,M
AU  - Schulze,MB
AU  - Rodriguez-Barranco,M
AU  - Vineis,P
AU  - Tumino,R
AU  - Kaaks,R
AU  - Fortner,RT
AU  - Sieri,S
AU  - Panico,S
AU  - Nøst,TH
AU  - Sandanger,TM
AU  - Braaten,T
AU  - Johansson,M
AU  - Melin,B
AU  - Johansson,M
DO  - 10.1002/ijc.34340
EP  - 2010
PY  - 2023///
SN  - 0020-7136
SP  - 2002
TI  - Assessment of the EarlyCDT-Lung test as an early biomarker of lung cancer in ever-smokers - A retrospective nested case-control study in two prospective cohorts
T2  - International Journal of Cancer
UR  - http://dx.doi.org/10.1002/ijc.34340
UR  - https://www.ncbi.nlm.nih.gov/pubmed/36305647
UR  - https://onlinelibrary.wiley.com/doi/10.1002/ijc.34340
UR  - http://hdl.handle.net/10044/1/100406
VL  - 152
ER  -
Download